| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shi-Ming Huang, Xiao-Bo Zhang, Jing Li, Guo-Hui Zhang, Xiao Zhang, Ying-Tian Wei, Hui Sun, Li Ma, Zhen-Jun Wang, Di-Xiao Yao, Hong-Jian Shi, Ti Wang and Yue-Yong Xiao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yue-Yong Xiao, Department of Radiology, The First Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. fszdk_301@163.com |
| Key Words |
Liver cancer; High-frequency irreversible electroporation; Programmed death-1/programmed death-ligand 1 inhibitor; Toll-like receptor 7/8 agonist; Antitumor immunity |
| Core Tip |
High-frequency irreversible electroporation potently triggers immunogenic cell death within tumors. In combination with BMS-1 and R848, this multimodal strategy not only curbs tumor progression but also dynamically reprograms the immunosuppressive tumor microenvironment. Specifically, it augments the infiltration of CD3+ CD4+ and CD3+ CD8+ T cells, CD11c+ CD80+ CD86+ dendritic cells, and F4/80+ CD11b+ CD86+ M1 macrophages, while depleting immunosuppressive subsets such as CD4+ CD25+ FOXP3+ regulatory T cells and F4/80+ CD11b+ CD206+ M2 macrophages. Consequently, the regimen induces a pronounced abscopal effect and fosters robust, systemic antitumor immunity, underscoring its translational potential as an innovative combination immunotherapy. |
| Publish Date |
2026-04-15 06:47 |
| Citation |
Huang SM, Zhang XB, Li J, Zhang GH, Zhang X, Wei YT, Sun H, Ma L, Wang ZJ, Yao DX, Shi HJ, Wang T, Xiao YY. High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity. World J Gastroenterol 2026; 32(15): 115226 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i15/115226.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i15.115226 |
